Anti-phosphorylcholine antibodies in cardiovascular disease

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the industrialized countries and a growing concern for the developing world. The underlying cause of almost all CVD is atherosclerosis, a process that is characterized by a low-grade inflammation in the artery walls. Thi...

Full description

Bibliographic Details
Main Author: Fiskesund, Roland
Format: Doctoral or Postdoctoral Thesis
Language:English
Published: Institutet för miljömedicin / Institute of Environmental Medicine 2013
Subjects:
Online Access:http://hdl.handle.net/10616/41826
id ftkarolinskainst:oai:openarchive.ki.se:10616/41826
record_format openpolar
spelling ftkarolinskainst:oai:openarchive.ki.se:10616/41826 2023-11-12T04:23:25+01:00 Anti-phosphorylcholine antibodies in cardiovascular disease Fiskesund, Roland 2013-12-17 application/pdf http://hdl.handle.net/10616/41826 eng eng Institutet för miljömedicin / Institute of Environmental Medicine I. Fiskesund R, Stegmayr B, Hallmans G, Vikstrom M, Weinehall L, de Faire U and Frostegard J. Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. Stroke. 2010 Apr; 41(4): 607-612. ::doi::10.1161/STROKEAHA.109.558742 ::pmid::20150554 ::isi::000276106100011 II. Fiskesund R, Su J, Bulatovic I, Vikström M, de Faire U, Frostegard J. IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with auto-antibodies against modified LDL. Results in Immunology. 2012. 2(0): 13-18. ::doi::10.1016/j.rinim.2012.01.001 III. Fiskesund R, Steen J, Amara K, Murray F, Szwajda A, Liu A, Douagi I, Malmström V and Frostegård J. Naturally occurring human phosphorycholine antibodies predominantly products of affinity-matured B cells in the adult. [Manuscript] 978-91-7549-434-0 http://hdl.handle.net/10616/41826 info:eu-repo/semantics/openAccess info:eu-repo/semantics/doctoralThesis dok 2013 ftkarolinskainst 2023-11-01T23:37:08Z Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the industrialized countries and a growing concern for the developing world. The underlying cause of almost all CVD is atherosclerosis, a process that is characterized by a low-grade inflammation in the artery walls. This inflammation is believed to be initiated by components of low density lipoproteins which, upon oxidation, display pro-inflammatory self-neo epitopes such as malonyldialdehyde (MDA) and phosphorylcholine (PC). Antibodies directed against the PC-epitope (anti-PC) have been researched for several decades but the relatively recent realization that these antibodies also recognize oxidized phospholipids has revolutionized the field and opened up a whole new avenue of investigation. Anti-PC has been shown to aid the clearance of apoptotic cells and prevent the formation of foam cells by clearing oxidized low density lipoprotein. Murine studies with PC-vaccination have shown strong beneficial effects on experimental atherosclerosis in vivo and human epidemiology has consistently linked anti-PC insufficiency to CVD. All humans have detectable anti-PC IgM in serum, though the concentration varies greatly between individuals. Our group has previously shown that people with low serum/plasma levels of anti-PC IgM have increased risk of CVD and the subgroup analysis had indicated that this association was particular strong with regard to the incidence of stroke. In paper I, we tested this hypothesis in a stroke material from northern Sweden. A significant association between low plasma level of anti-PC IgM at baseline and incident stroke was seen for the whole group at anti-PC levels below the 30th percentile (OR 1.62; CI 1.11 to 2.35). Analyses of gender-specific associations indicated fairly strong associations for females, especially at the lowest 30th percentile (OR 2.65; CI 1.41 to 4.95). However, no association was noted for men. Paper II focused on the properties of different anti-PC antibody classes/subclasses. We report ... Doctoral or Postdoctoral Thesis Northern Sweden Karolinska Institutet: Publications
institution Open Polar
collection Karolinska Institutet: Publications
op_collection_id ftkarolinskainst
language English
description Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the industrialized countries and a growing concern for the developing world. The underlying cause of almost all CVD is atherosclerosis, a process that is characterized by a low-grade inflammation in the artery walls. This inflammation is believed to be initiated by components of low density lipoproteins which, upon oxidation, display pro-inflammatory self-neo epitopes such as malonyldialdehyde (MDA) and phosphorylcholine (PC). Antibodies directed against the PC-epitope (anti-PC) have been researched for several decades but the relatively recent realization that these antibodies also recognize oxidized phospholipids has revolutionized the field and opened up a whole new avenue of investigation. Anti-PC has been shown to aid the clearance of apoptotic cells and prevent the formation of foam cells by clearing oxidized low density lipoprotein. Murine studies with PC-vaccination have shown strong beneficial effects on experimental atherosclerosis in vivo and human epidemiology has consistently linked anti-PC insufficiency to CVD. All humans have detectable anti-PC IgM in serum, though the concentration varies greatly between individuals. Our group has previously shown that people with low serum/plasma levels of anti-PC IgM have increased risk of CVD and the subgroup analysis had indicated that this association was particular strong with regard to the incidence of stroke. In paper I, we tested this hypothesis in a stroke material from northern Sweden. A significant association between low plasma level of anti-PC IgM at baseline and incident stroke was seen for the whole group at anti-PC levels below the 30th percentile (OR 1.62; CI 1.11 to 2.35). Analyses of gender-specific associations indicated fairly strong associations for females, especially at the lowest 30th percentile (OR 2.65; CI 1.41 to 4.95). However, no association was noted for men. Paper II focused on the properties of different anti-PC antibody classes/subclasses. We report ...
format Doctoral or Postdoctoral Thesis
author Fiskesund, Roland
spellingShingle Fiskesund, Roland
Anti-phosphorylcholine antibodies in cardiovascular disease
author_facet Fiskesund, Roland
author_sort Fiskesund, Roland
title Anti-phosphorylcholine antibodies in cardiovascular disease
title_short Anti-phosphorylcholine antibodies in cardiovascular disease
title_full Anti-phosphorylcholine antibodies in cardiovascular disease
title_fullStr Anti-phosphorylcholine antibodies in cardiovascular disease
title_full_unstemmed Anti-phosphorylcholine antibodies in cardiovascular disease
title_sort anti-phosphorylcholine antibodies in cardiovascular disease
publisher Institutet för miljömedicin / Institute of Environmental Medicine
publishDate 2013
url http://hdl.handle.net/10616/41826
genre Northern Sweden
genre_facet Northern Sweden
op_relation I. Fiskesund R, Stegmayr B, Hallmans G, Vikstrom M, Weinehall L, de Faire U and Frostegard J. Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. Stroke. 2010 Apr; 41(4): 607-612. ::doi::10.1161/STROKEAHA.109.558742 ::pmid::20150554 ::isi::000276106100011
II. Fiskesund R, Su J, Bulatovic I, Vikström M, de Faire U, Frostegard J. IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with auto-antibodies against modified LDL. Results in Immunology. 2012. 2(0): 13-18. ::doi::10.1016/j.rinim.2012.01.001
III. Fiskesund R, Steen J, Amara K, Murray F, Szwajda A, Liu A, Douagi I, Malmström V and Frostegård J. Naturally occurring human phosphorycholine antibodies predominantly products of affinity-matured B cells in the adult. [Manuscript]
978-91-7549-434-0
http://hdl.handle.net/10616/41826
op_rights info:eu-repo/semantics/openAccess
_version_ 1782338191642066944